Ranked by evidence
What actually helps perimenopause
Two lists. The first is everything a current guideline actually recommends, each with the grade its guideline gave it. The grades come from the sources. The order within a grade, and the length of each bar, are our reading and not something a panel published. The second list is everything sold hardest that did not survive review. Naming something as ineffective needs a source exactly as much as naming something effective does, so both lists carry them.
Free. No email required. No signup required. Takes about 2 minutes. Scored entirely in your browser: your answers are never stored or sent anywhere. Your score is shown next to the average for your age band.
What holds up
The bar on the right of each row is the weight of evidence behind the option, not the size of the effect you should expect. A short bar means the studies are small, few, or inconsistent, which is a different complaint from a treatment being weak.
-
01
The most effective treatment there is for hot flashes and night sweats, and the only thing on this list that also prevents bone loss. It is also the option with the longest list of things it does not fix.
EvidenceSTRONG
Menopause Society 2022: 75% fewer weekly episodes than placebo
-
02
Low dose vaginal oestrogen
For dryness, pain with sex, urgency and recurrent urinary infections. A different dose and a different risk conversation from the systemic kind, and preferred over it when this is the only complaint.
EvidenceSTRONG
Menopause Society 2020 GSM statement, Level A
-
03
Menopause-specific CBT
It does not stop the flashes. It changes how much they cost you, which is the outcome the trials chose to measure, and between 65% and 78% of participants crossed the threshold for meaningful improvement.
EvidenceSTRONG
Menopause Society 2023, Level I; NICE NG23 rec 1.5.2
-
04
Fezolinetant
A non-hormonal drug aimed at the brain circuit that fires a flash, rather than at the hormone that went missing. FDA approved for managing vasomotor symptoms. The NICE appraisal named beside this row is narrower: it recommends fezolinetant for moderate to severe symptoms only when HRT is unsuitable.5
EvidenceSTRONG
Menopause Society 2023, Level I; NICE TA1143
-
05
Clinical hypnosis
The entry on this list people laugh at. In a randomised trial of 187 women against an active control, hot flash frequency fell 74% against 17%, and follow-up found the effect was not explained by whether participants expected it to work.
EvidenceSTRONG
Menopause Society 2023, Level I
-
06
SSRIs and SNRIs
Mild to moderate relief, with reported reductions ranging widely across trials. Two guidelines disagree about where it belongs: recommended in the American statement, not routinely first line for heat alone in the UK one.
EvidenceMODERATE
Menopause Society 2023, Level I; NICE NG23 rec 1.5.4 disagrees
-
07
Gabapentin
Frequency and severity both improve. Drowsiness is the usual side effect, which is why it tends to be given at night and why it suits people whose worst hours are the small ones.
EvidenceMODERATE
Menopause Society 2023, Level I
-
08
Oxybutynin
A bladder drug that turned out to reduce moderate to severe flashes. Long term anticholinergic use carries its own questions about cognition in older people.
EvidenceMODERATE
Menopause Society 2023, Levels I to II
-
09
Weight loss
The only lifestyle change here that earned a recommendation at all, and it earned the weakest one on the list, from small and mostly uncontrolled studies. Larger trials are still owed.
EvidenceWEAK
Menopause Society 2023, Levels II to III
Nine entries. That is the whole of it, drawn from three current Menopause Society position statements and the current UK guideline.1234 Everything else on the shelf is in the next list.
What does not hold up
These were reviewed by the same panels, against the same literature, and turned down. Several carry Level I, the top grade these statements use, which means good and consistent scientific evidence behind the recommendation. It does not tell you which kind of no you are looking at. Paced breathing is the tested and failed kind: two larger trials found it no better than ordinary breathing. For the supplements, for black cohosh and for compounded hormones the same panels write lack of rigorous, evidence-based scientific research, insufficient evidence and lack of scientific efficacy and safety data, which is the other kind entirely: nobody has produced evidence anyone can use. Each row says which one it is.
-
-
Hormone balancing supplements
Assessed as a category and refused as a category. There is no rigorous evidence base supporting any over-the-counter supplement or herbal therapy for vasomotor symptoms, and nothing regulates what is actually in the capsule.
EvidenceNONE
Menopause Society 2023, not recommended, Levels I to III
-
-
Black cohosh
The most studied herb in the field, which makes the verdict worth more than usual: the evidence is insufficient to support using it.
EvidenceNONE
Menopause Society 2023, Level I, not recommended
-
-
Evening primrose oil
In the single trial, flashes fell by 1.0 a day on the oil and by 2.6 a day on the placebo. It lost to a sugar pill.
EvidenceNONE
Menopause Society 2023, Level II, not recommended
-
-
Compounded bioidentical hormones
Not the same thing as regulated body-identical oestradiol, which is on the list above. Insufficient efficacy data, real safety concerns about dosing and purity, and the saliva and urine tests used to prescribe them are unreliable.
EvidenceNONE
Menopause Society 2022, Level I safety concerns
-
-
Vaginal laser and radio-frequency
Costly, rarely covered by insurance, and the position statement asks for long term sham-controlled trials before routine use. Reported harms include scarring, lacerations and worse pain with sex.
EvidenceNONE
Menopause Society 2020, Level C, not recommended for routine use
-
-
Over-the-counter hormone test kits
At 45 or over, the guideline identifies perimenopause from recently started vasomotor symptoms and a change in your cycle, with no laboratory test at all, and names six tests specifically not to use.
EvidenceNONE
NICE NG23 recs 1.3.1 and 1.3.4
-
-
Yoga and exercise, for the flashes
Both are good for other things and the statement says so itself. For hot flashes: pooled across trials, exercise had no effect on how often they came, and yoga showed limited benefit against exercise and no benefit at all against no treatment.
EvidenceNONE
Menopause Society 2023, Level II, not recommended for VMS
-
-
Mindfulness-based programmes
A different verdict from the row above it, and the difference is the point. These studies generally improved menopause symptoms broadly with mixed effects on the flashes specifically, and they were small, short of a proper control group, or never designed to look at flashes at all. The conclusion is that there are not enough data to recommend it for this, which is not the same as finding that it failed.
EvidenceNONE
Menopause Society 2023, Level II, not enough data to recommend
-
-
Paced breathing
Graded at the strongest evidence level, and the finding is negative. Two larger trials found it no better than ordinary breathing, and one found slow breathing did worse than listening to music.
EvidenceNONE
Menopause Society 2023, Level I, not recommended
Read the yoga and exercise row narrowly. The review it comes from was scoped to hot flashes and night sweats from the start, and that is the outcome it graded. It does not say exercise is pointless; it says outright that these things carry other health benefits, and the same UK guideline separately tells clinicians to explain the importance of maintaining muscle mass and strength through physical activity.3
The gap in the middle of the map
Look back at the tags on the first list. Almost every one says Heat. That is not a coincidence and it is not our editorial choice: it is what the field measured. The 2023 review that produced most of the entries above was scoped to vasomotor symptoms from the start, and the outcome in nearly every underlying trial was hot flash frequency or hot flash bother.1
Which leaves a hole where the symptoms people actually arrive with should be. Rage. Waking at three in the morning. Joints that feel decades older than you are. The sensation of your own vocabulary going missing mid-sentence. For those, the honest answer is that the evidence thins fast, and in one case it is a flat negative: hormone therapy is not recommended at any age to prevent or treat a decline in cognitive function.2
Anyone selling you a clean answer for that middle band is selling you something. The list above is short because the field is small, not because we cut it.
Why it worked for me settles nothing
There is one number that explains most of the arguments in every comment section on this subject. Across trials of nonhormone treatments for vasomotor symptoms, the placebo improvement rate runs from 20% to 66%, and women with more anxiety respond to placebo more strongly.1
Two thirds of a room can improve on a dummy capsule. So a friend who felt better on a supplement is not lying to you, and neither is the reviewer with five stars. It just means a personal before and after cannot separate the pill from the passage of time, the season, the attention, or the hope. Only a comparison against a control can, which is why the grades in both lists above are worth more than the testimonials.
Where to start
The first entry has a page of its own, because a treatment this effective deserves the full account of its limits rather than a row in a table: HRT for perimenopause, what it fixes and what it doesn't.
Before any of it, though, the useful move is knowing what you are actually presenting with. Guidance identifies perimenopause at 45 or over from symptoms and cycle change alone, no blood test involved, which means the quality of your appointment depends almost entirely on how clearly you can describe the pattern.3 That is what the two-minute check is for.
Common questions
What actually helps perimenopause symptoms?
Nine options carry a positive recommendation in the current guidance: systemic hormone therapy, low dose vaginal oestrogen, menopause-specific cognitive behavioural therapy, fezolinetant, clinical hypnosis, SSRIs and SNRIs, gabapentin, oxybutynin and weight loss. Hormone therapy is the most effective of them for hot flashes and night sweats. Almost all of that evidence is about vasomotor symptoms, because that is the outcome nearly every trial in the field chose to measure.
Do menopause supplements work?
The 2023 nonhormone position statement assessed over-the-counter supplements and herbal remedies as a category and did not recommend them, citing a lack of rigorous evidence for any of them in vasomotor symptoms, and a lack of regulation over what a capsule actually contains. Black cohosh, the most studied of them, was graded at the strongest evidence level and found insufficient. In one trial evening primrose oil reduced flashes by 1.0 a day against 2.6 a day on placebo.
Does anything non-hormonal help hot flashes?
Yes, and more than most people are told. Menopause-specific cognitive behavioural therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin and fezolinetant all carry the strongest recommendation grade, and oxybutynin sits one level below. Two of those need no prescription at all. In one randomised trial of 187 women, clinical hypnosis reduced hot flash frequency by 74% against 17% in an active control group.
Why is exercise on the list of things that do not help?
Because the review those grades come from was scoped to hot flashes and night sweats, and pooled across trials exercise did not reduce them. That is a narrow finding and it should be read narrowly. The statement itself notes that exercise and yoga carry other health benefits, and the UK guideline separately tells clinicians to explain the importance of maintaining muscle mass and strength through physical activity. Nothing here says exercise is pointless; it says it is not a treatment for the heat.
Do I need a blood test to find out if this is perimenopause?
If you are 45 or over and otherwise healthy, the guideline says no. Perimenopause is identified from recently started vasomotor symptoms plus any change in your menstrual cycle, without laboratory tests, and the guideline names six tests specifically not to use for this at that age. Serum FSH is reserved for people aged 40 to 45, and for suspected premature ovarian insufficiency under 40.
Why does the same treatment get a different grade in different guidelines?
Because panels weigh the same trials differently. SSRIs and SNRIs are the clearest example on this page: the American position statement recommends them at its strongest evidence level, while the UK guideline says not to routinely offer them as first line treatment for vasomotor symptoms alone. Both are current. Where two current guidelines disagree, this page says so rather than picking the more convenient one.
My friend swears by a supplement. Is she wrong?
Not about how she felt. Across trials of nonhormone treatments for vasomotor symptoms the placebo improvement rate runs from 20% to 66%, and women with more anxiety respond more strongly to placebo. So a genuine personal improvement is entirely expected on something inert, which is why a before and after cannot separate the treatment from time, season, attention or hope, and why a controlled comparison can.
Start with the pattern, not the shelf
Which of these is worth discussing depends on what you actually have. Nineteen symptoms across four domains, plus your cycle, scored against the average for your age band and printable for the appointment.
The shortest list on this page is the useful one, and nobody is paid to show it to you.
Take the 2-minute checkFree, no email, no signup. Scored entirely in your browser. Screening, not diagnosis. No provider is linked from this page and nothing on it is sponsored.
HRT for perimenopause
What a perimenopause test can tell you
The symptoms checklist
Is this perimenopause anxiety?